FDA approves Pfizer, German Merck immunotherapy for skin cancer – Nasdaq
Nasdaq |
FDA approves Pfizer, German Merck immunotherapy for skin cancer
Nasdaq It marks the first immunotherapy approval for the collaboration of Pfizer and Germany-based Merck, which has been playing catch-up with rivals, such as Bristol-Myers Squibb Co <BMY.N>, Merck & Co <MRK.N> and Roche Holding AG <ROG.S>. "While skin … |
